Navigation Links
Trans fatty acids increase the risk of gallstone,,disease.

Several studies have shown that consumption of trans fatty acids leads to development of diabetes, cancer and cardiovascular disease.// Trans fatty acids are the hydrogenated and partially hydrogenated oil present in some margarines, candies, baked goods and many processed foods. They are produced commercially in large quantities by heating vegetable oils in the presence of metal catalysts and in the process the poly unsaturated fatty acids are removed. Trans fatty acids increase LDL cholesterol (the bad cholesterol) and decrease HDL cholesterol (the good cholesterol )thereby increasing the risk of heart disease.

A prospective study published in the May issue of the Archives of Internal Medicine has shown that higher consumption of trans fatty acids increased the risk of gallstone disease. The study was performed by applying a semi quantitative questionnaire that had questions relating to the food and frequency of food intake to a cohort of nearly 46000 men twice a year. Patients diagnosed with gallstone disease based on the X ray and cholecystectomy findings were recorded. During 14 years of follow-up, 2356 new cases of patients with symptoms who had gallstones were recorded. The result which was adjusted for difference in age and other associated risk factors showed that those men who had taken higher amounts trans fatty acids had a greater relative risk(1.23) of gallstone diseases compared with those who had taken lower amounts. Among the subtypes of trans fatty acids risk was more with trans-oleic fatty acid as compared to the other types. Intake of the unsaturated vegetable oils from canola, peanuts, olive, flax, corn, safflower and sunflower which contain monounsaturated or polyunsaturated fatty acids that can reduce total cholesterol and increase HDL cholesterol levels assumes significant importance in this context. So play it safe by eating safe.

Reference
Arch Intern Med. 2005;165:997-10 03.
'"/>




Related medicine news :

1. Transdermal HRT not cardioprotective in postmenopausal women with CAD
2. Transdermal HRT not cardioprotective in postmenopausal women with Coronary Artery Disease
3. Stem Cell Transplants May Be Effective For MS Patients
4. Transforming stem cells to lung cells
5. Alternative to blood Transfusions
6. Need for Blood Transfusions reduced
7. Drugs Deter Heart Disease for Transplant Patients
8. Better Drug for Heart Transplant
9. Kidney Failure after Non-Kidney Transplants
10. Measles Risk in Transplant Patients
11. West Nile and Blood Transfusions
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/29/2016)... ... 29, 2016 , ... Melanoma is the deadliest type of skin cancer. Although only about 1 ... skin cancer deaths. More than 10,000 people are expected to die of melanoma this year. ... is the one of the most commonly diagnosed cancers in young women. A recent breakthrough ...
(Date:4/29/2016)... ... April 29, 2016 , ... Reltok Nasal Products proudly announces that Boston ... and neck/ear, nose and throat specialty, has added the KOTLER NASAL AIRWAY™ to its ... is a newly patented safety device secured by nasal surgeons onto the floor ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... Dairy Products, Inc. in an upcoming episode, airing third quarter 2016 via Discovery ... churning cream into butter, Grassland Dairy Products, located in Greenwood, Wisconsin applies product ...
(Date:4/29/2016)... ... April 29, 2016 , ... The infertility specialists at HRC Fertility/Orange County ... Dr. Daniel A. Potter -- are proud of the recent release of their 2014 ... April, SART published the latest verified data for 375 U.S. member clinics. ...
(Date:4/29/2016)... ... 29, 2016 , ... International Dehydrated Foods, Inc. (IDF™) will attend and sponsor ... the Doubletree by Hilton Hotel in Oak Brook, Illinois. The two-day event is the ... protein ingredients. , At the seminar, IDF™ will offer samples of its Savory ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... , Net Sales of $1.90 billion represent an increase ... period, and an increase of 1.2% on an adjusted pro ... first quarter were $0.52 reported, a decrease of 47.5% from ... 29.9% over the prior year period , The Company ... Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) ...
(Date:4/28/2016)... April 28, 2016  ValGenesis, Inc., the ... Solutions (VLMS) today announced that a prominent ... sufferers of chronic kidney failure has selected ... their corporate validation process. The global medical ... solution to manage their validation processes electronically. ...
(Date:4/27/2016)... , Schweiz, April 27, 2016 /PRNewswire/ ... des Sachs CEO Forums in Zürich gab ... ihres führenden Wirkstoffkandidaten STR001 zur Erhaltung des ... eingesetzt wurde, bekannt. Für die umfassende Phase-II-Doppelblindstudie ... und Frankreich angeworben. STR001 wird während der ...
Breaking Medicine Technology: